Background The lack of an ideal cell type that can be easily acquired, modified to produce insulin, and re-implanted has been a limitation for ex vivo insulin gene therapy. Canine diabetes is currently treated with human insulin and is a good model for human diabetes. Mesenchymal stromal cells (MSCs) are a promising candidate cell type for gene therapy. In the present study, we optimised insulin production using lentiviral transduced canine MSCs (cMSCs), aiming to evaluate their ability for use as surrogate beta cells.
particular disease, has significant potential for treatment of a diseases such as diabetes, where treatment involves restoration of functional levels of a protein. Insulin production in non-beta cells is being attempted by exogenous insulin gene expression using either viral or nonviral methods of gene delivery. 4, 5 Their natural glucose-sensing capability and the ability to undergo glucose-stimulated transcription make hepatocytes attractive as surrogate beta cells. Although insulin gene therapy using hepatocytes has shown considerable promise in murine models of diabetes, with some studies even reporting a cure, lasting correction of blood glucose has not yet been reported in a preclinical model. 6, 7 Furthermore, the use of autologous hepatocytes for clinical application may not be easily scalable for clinical use. 8 Skeletal muscle cells have been targeted by direct injection of modified adeno-associated virus serotype 1 (AAV1) encoding both the insulin gene and a glucokinase gene, into the thigh muscles of diabetic dogs as an in vivo insulin therapy. 5 In vivo insulin gene therapy not only has its benefits, but also presents safety concerns regarding potential offtarget cell transduction and the risk of irreversible hypoglycaemia from excessive insulin production. [9] [10] [11] Ex vivo gene therapy using retroviruses has been used for successful treatment of severe combined immunodeficiencies for over a decade and has represented a significant milestone in gene therapy, although a number of patients developed leukaemia as a result of insertional mutagenesis. 9, [11] [12] [13] Ex vivo insulin gene therapy for the treatment of diabetes has, until now, been limited by the availability of an appropriate cell lineage for insulin production.
Mesenchymal stromal cells (MSCs) are multipotent cells that are able to differentiate into cell types of mesodermal origin, such as osteoblasts, chondroblasts and adipocytes. 14 MSCs can be readily isolated from the bone marrow based on their ability to adhere to plastic culture dishes and identified by their spindle-shape morphology. 15 They can be easily re-implanted after genetic modification and show long-term engraftment following transplantation, thereby proving a good potential candidate cell type for use in ex vivo gene therapy. 16 They have also attracted considerable attention as a potential tool for therapeutic gene transfer. [17] [18] [19] [20] [21] Lentiviral vectors based on HIV type 1 are emerging as vectors of choice for ex vivo and in vivo gene therapy in a number of scenarios.
HIV 1 vector-based gene delivery depends on using the HIV packaging signal and other viral cis-acting sequences to encapsidate the desired gene to be delivered via a lentiviral particle. [22] [23] [24] [25] Their advantages include a large gene capacity of up to 8 kb, the ability to infect dividing and nondividing cells, the absence of inflammatory/immune response induction, and long-term transgene expression. In addition pseudotyping lentiviral vectors with vesicular stomatitis virus envelope broadens the cell tropism by increasing the number of potential target cell types.
We aimed to carry out a proof-of-principle study for cell-based gene therapy applicable to Type I or insulin-requiring Type II diabetes.
Diabetes is a relatively frequent condition in dogss and human insulin is the standard therapy. Complications occur, as in human diabetes, and difficulties with repeated needle usage are well recognised in both pets and by their owners. Cell-based insulin gene therapy with autologous canine MSCs (cMSCs) would provide a highly workable treatment and provide a stepping stone to this approach in humans.
Specifically, in the present study, we aimed to (i) establish the feasibility of culturing primary cMSCs; (ii) provide in vitro proof of lentiviral transduction and insulin secretion by cMSCs; (iii) compare the ability of different viral and mammalian constitutive promoters to drive insulin gene expression in cMSCs; and (iv) investigate the effect of long-term culture on viral promoter expression in transduced cells.
We envisaged that implantation of autologous insulin-producing cMSCs could provide an in vivo source of constitutive basal insulin secretion to prevent hyperglycaemia between meals and at night.
The results of the present study would provide the precursor to the much more challenging goal of glucose responsive gene therapy, which has yet to be achieved. provided their written informed consent to allow the use any cells obtained as part of routine work in the clinic for 'research to the benefit of animal welfare'. The bone marrow cells acquired were always obtained as part of routine and recognized diagnostic testing or treatment procedures and the procedure caused no unnecessary distress or harm to the dogs (i.e. samples were never to be taken for research-only reasons and excessive sampling was also not permitted).
Cells were cultured in custom-made MSC media; 33% (v/v) low glucose DMEM, 67% (v/v) complete MSC media (Life Technologies, Paisley, UK), 10% heat-inactivated fetal bovine serum (HyClone, GE Healthcare Life Sciences, Logan, UT, USA), 100 IU/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. Adherent MSCs adopted a spindle-shape morphology in culture and were expanded for up to 21 days. Once the cells reached over 80% confluence in a T175 flask, the cells were frozen at a concentration of one million cells per ml in freezing media (90% FCS, 10% dimethyl sulphoxide v/v). 
| Lentiviral vector construction

| Virus production
Replication deficient HIV-1 based lentiviruses were produced by transient cotransfection involving a three plasmid system. 27 (Figure 1b ). 28 
| Flow cytometry
| Lentiviral transduction of primary cMSCs
To assess the lentiviral transduction efficiency of primary cMSCs, lenti SFFV Ins (F) IRES GFP and lenti SFFV GFP (mock) vectors (Figure 2a) were used to produce lentiviral vectors and transduce primary cMSCs.
Mock vector expressing GFP but not insulin (lenti SFFV GFP) was used as a negative control for insulin secretion and as a positive control for viral transduction. Physiologically, insulin is transcribed and translated as a pre-prohormone; a single polypeptide chain of 100 amino acids comprises, sequentially, a signal peptide, the beta chain, a connecting (C-) peptide and the alpha chain. 29 Following translation, the signal peptide of pre-proinsulin is removed to form proinsulin. Proinsulin is further processed to form mature insulin, which consists of two individual alpha and beta chains joined together by two disulphide bridges.
C-peptide is released in the process. Therefore, insulin and C-peptide are produced in a 1:1 ratio from proinsulin. 29 Because the lenti-SFFV Insulin (F) IRES GFP virus encodes the proinsulin and the GFP gene, we used the concentration of C-peptide in the medium of transduced cells, as well as the expression of GFP, to measure the transduction efficiency. 30 Fluorescence microscopy of cMSCs confirmed successful GFP reporter gene expression in lenti-SFFV Ins (F) IRES GFP transduced cells (Figure 2b ). As the MOI increased from 3 to 20, there was a statistically significant increase in the percentage of cells expressing GFP (60% to 80%) and an increase in the concentration of human Cpeptide (from 1700 to 4000 pmol/l), which was statistically significant at MOI 10 and 20 in the medium of the transduced cMSCs and consistent with the published literature ( Figure 2c ). 30, 31 A time-course experiment was performed to assess the accumula- (Figure 2d ). There was a significant increase in concentration of C-peptide in the medium with increasing time post transduction in cMSCs transduced with lenti-SFFV Ins(F) GFP. This observation of an exponential phase, a transition phase and a plateau phase in protein secretion after lentiviral transduction is consistent with the published data. 32 Transcriptional activities of four constitutive promoters in primary cMSCs and Hep3B cells.
Next, we evaluated whether the SFFV promoter used was the optimal promoter for lentiviral transduction of primary cMSCs. We generated lentiviral vectors that were isogenic other than being driven by different constitutive promoters and compared these with the original vector driven by the SFFV promoter ( Figure 3a) . Two of the three were virus-derived constitutive promoters (CMV, SV40); the third was (Figure 3b ). The SFFV promotor was also the only promotor to evoke a statistically significant increase in C-peptide secretion.
The amount of GFP detected was similar using the four constitutive promoters in both the cMSCs and the Hep3B cells, although there was a large difference in the amount of C-peptide detected in the medium (Figure 3c ). This may be a result of the difference in stability between the two proteins (the half-lives of GFP and C-peptide are 24 h and 20-30 min, respectively). 33, 34 Therefore, the difference in the percentage of cells expressing GFP between the different promoters may be masked by the relative stability of expressed GFP protein. Nevertheless, the SFFV promoter within the lentiviral vector conferred the strongest transcriptional activity in cMSCs at 72 h post transduction.
| Optimisation of lentiviral vector mediated insulin expression by cMSCs
To further optimise insulin gene expression in cMSCs, lentiviral vectors encoding a Kozak consensus sequence (GCCGCCACC) directly upstream of the insulin gene transcription start site were generated.
Kozak consensus sequences play an important role in initiation of protein translation. 35 Figure 4b shows that the addition of the Kozak consensus sequence produces a statistically significant (p < 0.0001) increase in the amount of C-peptide secreted by the transduced cMSCs. In addition, the percentage of cells expressing GFP was higher when cMSCs were transduced with a Kozak sequence containing viral Future in vivo experiments would require the removal of the IRES-GFP reporter genes from the lentiviral vector. Therefore, to ensure that the removal of reporter gene does not lead to a significant alteration in transduction efficiency, we generated a lentiviral vector without the IRES GFP gene (Figure 4c Transcriptional activities of promoters have been shown to decrease with time in permanently transduced cells. 32, 36 Additionally, we have previously reported that early GFP protein 'expression' seen in transduced cells can be a result of virally translated GFP protein in the vector producer cell rather than representing the true levels of transgene integration and cellular GFP protein synthesis. 37 Therefore, cMSCs transduced with each of the four constitutive promoters were kept in culture and the amount of C-peptide and GFP expressed was measured at days 3, 7 and 21 after transduction. This assay demonstrated that, despite the SFFV promoter inducing the highest amount of C-peptide secretion and GFP expression among the four promoters when compared at day 3 post transduction, at days 7 and 21, the level of protein expression by the SFFV promoter was similar to that of SV40 and EF1α promoters (p < 0.0001) (Figures 5a and 5b) . The percentage of GFP expression in cMSCs transduced with lentivirus containing the viral constitutive promoter CMV and the mammalian constitutive promoter EF1α were slightly lower at day 21 than that seen at day 3 post transduction (Figures 2b and 5b) . Analysis of MSC surface markers showed that the cells were positive for the MSC marker CD29 and CD90 and negative for the haematopoietic markers CD34, CD14 and CD45 despite long-term culture (Figure 5c ). In addition, the expression levels of the surface markers from these cells were similar to that observed in untreated cells (Figures 1a and 5c ), suggesting that long-term culture of transduced cMSCs did not alter their phenotype. Overall, these assays demonstrate that the SFFV promoter is an optimal promoter at driving transgene expression in cMSCs short-and long-term (up to 21 days) and emphasises the stability of phenotype of transduced cMSCs.
| DISCUSSION
MSCs are promising candidate cells for ex vivo insulin gene therapy.
They are easily obtained from bone marrow, are readily transduced with lentiviruses, and can be reimplanted autologously into donor animals. 17, 19 In the present study, we show that the expression of C-peptide measurements are considered to be considerably more reliable indicators of insulin secretion than direct insulin measurements 33 in part because, unlike mature insulin, there is no reassociation of C-peptide with producer cells. In addition, the half-life of secreted insulin in vivo may be as low as 4 min, whereas that of Cpeptide is generally considered to be at least five times as long. Thus, the time window for accurate measurement of C-peptide makes it a far better reflection of secreted insulin than any attempt to factor in the rapid degradation of insulin that occurs between sampling media and freezing for diagnostic assay. C-peptide is also far more stable at room temperature than is insulin. 38 The SFFV promoter conferred the strongest transcriptional ability in primary cMSCs at 72 h post transduction (as judged by C-peptide production and GFP expression). Expression from CMV, SV40 and EF1α promoters at an identical MOI was less efficient. The CMV promoter conferred the weakest transcriptional ability in primary cMSCs. This is a somewhat surprising finding because this is widely reported as a strong promoter. 39, 40 However, the strength of gene expression is variable and dependent on the cell type. [39] [40] [41] Furthermore, the percentages of cells expressing GFP were similar in cells transduced with all four different promoter-containing vectors in both cell types. This confirms that the observed difference in concentration of C-peptide produced by cells transduced with lentiviral vectors with four different internal promoters is not a result of differences in transduction efficiency. We observed a more than 1.5-fold increase in both C-peptide and GFP expression when a Kozak consensus sequence was added upstream of the proinsulin gene. This result is consistent with the published data. 42 The Kozak consensus sequence has become increasingly valuable as a tool for improving gene expression using viral constructs since its discovery in 1987 and has been incorporated in multitude of expression studies. Removal of the downstream IRES GFP from the lentiviral vector did not influence C-peptide secretion. rising to a peak and then plateauing is an encouraging indicator showing that stable expression can be expected using this approach. This was further validated by the observation that primary cMSCs sustained their level of transgene expression when kept in culture for up to 21 days post transduction. There was no evidence of the silencing of any promoter in cMSCs when tested at day 21. This is consistent with our previous findings indicating that, once a lentiviral vector has integrated and is expressing a transgene, it is rarely switched off. 43 Additionally, there was no difference in the expression of the MSC marker CD29 and stem cell marker CD34 before transduction, at 72 h post transduction or at day 21 post transduction, suggesting that the MSCs maintained their state of differentiation in culture and post transduction.
In humans, only 10% of the physiological circulating insulin level is required to prevent life-threatening diabetic ketoacidosis. 44 Thus, a constitutive basal level of insulin secretion would be expected to increase glycaemic control and the quality of life of diabetic patients.
Insulin gene therapy that provides a basal level of insulin could also serve as a substitute that is currently provided via the exogenous administration of long-acting insulin. Continuous low-level insulin secretion by ex vivo modified MSCs, as reported in the present study, is therefore also a promising alternative approach to continuous subcutaneous insulin infusion therapy. The latter has been shown to successfully reduce glycosylated haemoglobin A1c, with a concomitant decrease in the rate of hypoglycaemic events and without excessive weight gain. 45, 46 Insulin supplementation could also be particularly attractive in treatment of insulin-dependent type II diabetes where the disease in not immune mediated and therefore autoimmune destruction of insulin-producing transplanted cells is unlikely to occur. Furthermore, such a supplemental source of insulin from transduced MSCs would decrease the work load of the remaining beta cells in the pancreas, potentially allowing beta cell recovery. The remaining beta cells then would only need to provide the postprandial glucose-dependent insulin secretion.
Further in vivo studies in diabetic animal models will be required to (i) optimise the viral dose; (ii) investigate the in vivo retention, mobilisation and stability of ex vivo modified insulin secreting MSCs;
and (iii) assess the risk of an immune mediated response towards insulin-producing transplanted cells. There is a potential risk of development of hypoglycaemia with constitutive insulin secretion. This can be mitigated by titration of the viral dose, providing a way of regulating constitutive insulin production. Ideally a glucose-regulated insulin secretion system would be utilised but, to date, the regulated promoters that have been tested have been either too slow or not reliable in their responsiveness to glucose. 4, 47, 48 In conclusion, the data obtained in the present study demonstrate that lentiviral transduction of the insulin genes into primary cMSCs derived from the bone marrow is a promising way forward for establishing the secretion of insulin, both over the short-and longterm.
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